ADGM

Adagio is a clinical-stage medical-device company, not an operating business. FY2025 revenue was $0.00 (down from $300K in FY2023), so every conventional valuation lens — P/E, P/S, growth-adjusted — is meaningless. What you are buying at $0.64 is a single-product regulatory option: the vCLAS ULTA cryoablation system for ventricular tachycardia, whose FULCRUM-VT pivotal IDE trial completed 209-patient enrollment in October 2025 and carries FDA Breakthrough Device Designation. The company plans six-month data at Heart Rhythm 2026 (April) and an FDA submission in H1 2026. Everything about the equity hinges on that outcome, which is unknowable from the data here — the definition of the rubric's 'avoid.'

The balance sheet makes the timing hostile. Cash is $17.1M and falling (-16.9% YoY) against operating cash burn of -$19.0M per year — roughly under twelve months of runway before any commercialization revenue exists. Long-term debt rose to $21.0M (+22.5%) and liabilities/equity sits at 2.49x, so a chunk of the thin $12.4M equity is already spoken for; retained deficit is -$95.6M. Shares outstanding jumped 44.4% in a year to 22.2M — dilution is not a tail risk, it is the funding model, and a sub-$1 stock raising into a binary event is a recipe for severe per-share erosion. The 'improving' net loss (-$25.1M, +31.4% YoY) and R&D down 30.9% reflect cost discipline, but cutting R&D at a company whose entire value is its pipeline is a double-edged signal about cash preservation.